Company Description
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia.
The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.
Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing.
The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases.
It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Country | Malaysia |
Founded | 2017 |
Industry | Specialty Chemicals |
Sector | Materials |
Employees | 30 |
CEO | Su-Leng Tan |
Contact Details
Address: Tower B, Avenue 3, Unit 02, Level 10 Kuala Lumpur, 59200 Malaysia | |
Phone | 60 1 307 241 6898 |
Website | bionexusgenelab.com |
Stock Details
Ticker Symbol | BGLC |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001737523 |
CUSIP Number | 090628108 |
ISIN Number | US0906282076 |
Employer ID | 26-2124961 |
SIC Code | 8071 |
Key Executives
Name | Position |
---|---|
Su-Leng Tan | Chief Executive Officer, Acting Chief Financial Officer, Secretary and Director |
Kwan Wah Chan | Marketing Manager |
Too Kam Tham | Managing Director |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 15, 2024 | 10-Q | Quarterly Report |
Nov 14, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
Nov 8, 2024 | 8-K | Current Report |
Oct 15, 2024 | 8-K | Current Report |
Oct 10, 2024 | 8-K | Current Report |
Sep 25, 2024 | 8-K | Current Report |
Sep 18, 2024 | 8-K | Current Report |
Sep 16, 2024 | DEF 14A | Other definitive proxy statements |
Sep 12, 2024 | 8-K | Current Report |
Sep 6, 2024 | PRE 14A | Other preliminary proxy statements |